Cargando…
1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472552/ http://dx.doi.org/10.1016/j.annonc.2022.07.1746 |
| _version_ | 1784789326645690368 |
|---|---|
| author | Debie, Y. Van Audenaerde, J. Vandamme, T. Croes, L. Teuwen, L-A.M.N. Verbruggen, L. Vanhoutte, G. Marcq, E. Le Blon, D. Peeters, B. M.E. Goossens Arien, K. Anguille, S. Smits, E. Vulsteke, C. Lion, E. Peeters, M. van Dam, P.A. |
| author_facet | Debie, Y. Van Audenaerde, J. Vandamme, T. Croes, L. Teuwen, L-A.M.N. Verbruggen, L. Vanhoutte, G. Marcq, E. Le Blon, D. Peeters, B. M.E. Goossens Arien, K. Anguille, S. Smits, E. Vulsteke, C. Lion, E. Peeters, M. van Dam, P.A. |
| author_sort | Debie, Y. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9472552 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94725522022-09-14 1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients Debie, Y. Van Audenaerde, J. Vandamme, T. Croes, L. Teuwen, L-A.M.N. Verbruggen, L. Vanhoutte, G. Marcq, E. Le Blon, D. Peeters, B. M.E. Goossens Arien, K. Anguille, S. Smits, E. Vulsteke, C. Lion, E. Peeters, M. van Dam, P.A. Ann Oncol Article European Society for Medical Oncology. Published by Elsevier Ltd. 2022-09 2022-09-13 /pmc/articles/PMC9472552/ http://dx.doi.org/10.1016/j.annonc.2022.07.1746 Text en Copyright © 2022 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Debie, Y. Van Audenaerde, J. Vandamme, T. Croes, L. Teuwen, L-A.M.N. Verbruggen, L. Vanhoutte, G. Marcq, E. Le Blon, D. Peeters, B. M.E. Goossens Arien, K. Anguille, S. Smits, E. Vulsteke, C. Lion, E. Peeters, M. van Dam, P.A. 1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients |
| title | 1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients |
| title_full | 1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients |
| title_fullStr | 1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients |
| title_full_unstemmed | 1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients |
| title_short | 1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients |
| title_sort | 1666p lower virus neutralizing titers against sars-cov-2 omicron strain after third dose bnt162b2 following primo-vaccination with chadox1 versus bnt162b2 in cancer patients |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472552/ http://dx.doi.org/10.1016/j.annonc.2022.07.1746 |
| work_keys_str_mv | AT debiey 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT vanaudenaerdej 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT vandammet 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT croesl 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT teuwenlamn 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT verbruggenl 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT vanhoutteg 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT marcqe 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT leblond 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT peetersb 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT megoossens 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT arienk 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT anguilles 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT smitse 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT vulstekec 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT lione 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT peetersm 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients AT vandampa 1666plowervirusneutralizingtitersagainstsarscov2omicronstrainafterthirddosebnt162b2followingprimovaccinationwithchadox1versusbnt162b2incancerpatients |